IntoCell, Inc. (KOSDAQ:287840)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021
Antibody-drug Conjugate	2.91B
Antibody-drug Conjugate Growth	79.72%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021
South Korea	2.88B
United States	13.04M
United States Growth	119.53%
China	12.22M
China Growth	-84.08%